Including tumor-infiltrating lymphocytes into the PREDICT prognostic model for triple-negative breast cancer survival.
Wang Y, Drubay D, Jonas SF, Dixon-Douglas J, Acs B, Adams S, André F, Badve S, Bataillon G, Carter JM, Chia S, Cockenpot V, Colleoni MA, Criscitiello C, Curigliano G, Dackus GMHE, Demaria S, Denkert C, van Deurzen CHM, Dieci MV, Giardiello D, Goetz MP, Gray RJ, Hauptmann M, Ter Hoeve ND, Jóźwiak K, Koop EA, de Jong VMT, Joensuu H, Jules-Clément G, Kammler R, Kellokumpu-Lehtinen PL, Kim SB, Kok M, Lacroix-Triki M, Lambertini M, Lee HJ, Lemonnier J, Leon-Ferre RA, Leung S, Linderholm B, Loibl S, Martens JWM, Nielsen TO, Opdam M, Pharoah P, Penault-Llorca F, Piccart M, Pusztai, Riaz N, Vincent-Salomon A, Sparano J, Shimoi T, Sotiriou C, Suman VJ, Timmermans AM, van Diest PJ, Voogd AC, Viale G, Wolff AC, Yazaki S, Yoshida M, Salgado R, Linn SC, Schmidt MK, Loi S, Michiels S; A report on behalf of the International Immuno-Oncology Biomarker Working Group.
Wang Y, et al. Among authors: timmermans am.
Ann Oncol. 2026 Aug;37(8):1093-1105. doi: 10.1016/j.annonc.2026.04.011. Epub 2026 Apr 21.
Ann Oncol. 2026.
PMID: 42025762